|
|
Blood, 1 April 2005, Vol. 105, No. 7, pp. 2845-2851.
Prepublished online as a Blood First Edition Paper on December 9, 2004; DOI 10.1182/blood-2004-07-2959.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR
Barbara Valzasina,
Cristiana Guiducci,
Heidrun Dislich,
Nigel Killeen,
Andrew D. Weinberg, and
Mario P. Colombo
From the Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; the Department of Microbiology and Immunology, University of California, San Francisco; and Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, OR.
OX40 (CD134) is a member of the tumor necrosis factor (TNF) receptor family that is transiently expressed on T cells after T-cell receptor (TCR) ligation. Both naive and activated CD4+CD25+ regulatory T cells (T reg's) express OX40 but its functional role has not been determined. Since glucocorticoid-induced tumor necrosis factor receptor (GITR), a related TNF receptor family member, influences T reg function, we tested whether OX40 might have similar effect. Triggering either GITR or OX40 on T reg's using agonist antibodies inhibited their capacity to suppress and restored effector T-cell proliferation, interleukin-2 (IL-2) gene transcription and cytokine production. OX40 abrogation of T reg suppression was confirmed in vivo in a model of graft-versus-host disease (GVHD). In a fully allogeneic C57BL/6>BALB/c bone marrow transplantation, GVHD was lethal unless T reg's were cotransferred with the bone marrow and effector T cells. Strikingly, T reg suppression of GVHD was abrogated either by intraperitoneal injection of anti-OX40 or anti-GITR monoclonal antibodies (mAbs) immediately after transfer, or by in vitro pretreatment of T reg's with the same mAbs before transfer. Cumulatively, the results suggest that in addition to controlling memory T-cell numbers, OX40 directly controls T reg–mediated suppression.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Hirschhorn-Cymerman, G. A. Rizzuto, T. Merghoub, A. D. Cohen, F. Avogadri, A. M. Lesokhin, A. D. Weinberg, J. D. Wolchok, and A. N. Houghton
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
J. Exp. Med.,
May 11, 2009;
206(5):
1103 - 1116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Szymczak-Workman, C. J. Workman, and D. A. A. Vignali
Cutting Edge: Regulatory T Cells Do Not Require Stimulation through Their TCR to Suppress
J. Immunol.,
May 1, 2009;
182(9):
5188 - 5192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Houot and R. Levy
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy
Blood,
April 9, 2009;
113(15):
3546 - 3552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Guerin, J. R. Prins, and S. A. Robertson
Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment?
Hum. Reprod. Update,
March 11, 2009;
(2009)
dmp004v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Wilde, S. Dolff, X. Cai, C. Specker, J. Becker, M. Totsch, U. Costabel, J. Durig, A. Kribben, J. W. C. Tervaert, et al.
CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosis
Nephrol. Dial. Transplant.,
January 1, 2009;
24(1):
161 - 171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Gough, C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, and A. D. Weinberg
OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor
Cancer Res.,
July 1, 2008;
68(13):
5206 - 5215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tao, L. Wang, K. M. Murphy, C. C. Fraser, and W. W. Hancock
Regulatory T Cell Expression of Herpesvirus Entry Mediator Suppresses the Function of B and T Lymphocyte Attenuator-Positive Effector T Cells
J. Immunol.,
May 15, 2008;
180(10):
6649 - 6655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Piconese, B. Valzasina, and M. P. Colombo
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
J. Exp. Med.,
April 14, 2008;
205(4):
825 - 839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Ruzek, J. S. Waire, D. Hopkins, G. LaCorcia, J. Sullivan, B. L. Roberts, S. M. Richards, S. R. Nahill, J. M. Williams, A. Scaria, et al.
Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells that inhibit graft-versus-host disease in vivo
Blood,
February 1, 2008;
111(3):
1726 - 1734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ramirez-Montagut, A. Chow, D. Hirschhorn-Cymerman, T. H. Terwey, A. A. Kochman, S. Lu, R. C. Miles, S. Sakaguchi, A. N. Houghton, and M. R. M. van den Brink
Glucocorticoid-Induced TNF Receptor Family Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma Differentiation Antigens and Enhances Antitumor Immunity.
J. Immunol.,
June 1, 2006;
176(11):
6434 - 6442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Cohen, A. Diab, M.-A. Perales, J. D. Wolchok, G. Rizzuto, T. Merghoub, D. Huggins, C. Liu, M. J. Turk, N. P. Restifo, et al.
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity.
Cancer Res.,
May 1, 2006;
66(9):
4904 - 4912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Murata, B. H. Ladle, P. S. Kim, E. R. Lutz, M. E. Wolpoe, S. E. Ivie, H. M. Smith, T. D. Armstrong, L. A. Emens, E. M. Jaffee, et al.
OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen
J. Immunol.,
January 15, 2006;
176(2):
974 - 983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
